Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
19 Ergebnisse für "silibinin" unter Somagenetix
Efficacy of lead-in silibinin and subsequent triple therapy in diff...
... Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C ... with silibinin before triple therapy in difficult-to-treat patients. Methods: Inclusion criteria were ... Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C ... Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C ... Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C ...
Hepatocellular organic anion-transporting polypeptides (OATPs) and ...
... inhibited by silibinin. Drug Metabolism and Disposition, 41(8):1522-1528. Copy Abstract Silibinin has been ... . Although administered silibinin is well tolerated, increased serum bilirubin levels have been observed ... protein 2 (MRP2) are inhibited by silibinin - Zurich Open Repository and Archive Header Quicknavigation ... polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are inhibited by silibinin Wlcek ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
9 Ergebnisse für "silibinin" unter University of Zurich
Curriculum Vitae
... ; Multiple funders including UZH) 2013-2014 THISTLE: A Silibinin trial in HCV-HIV coinfection (Sponsor ... ; Multiple funders including UZH) 2013-2014 THISTLE: A Silibinin trial in HCV-HIV coinfection (Sponsor ...
Browse by Communities & Collections - Zurich Open Repository and Archive
... multidrug resistance-associated protein 2 (MRP2) are inhibited by silibinin. Drug Metabolism and Disposition ...
University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
6 Ergebnisse für "silibinin" unter University Hospital Zurich, Research and Education Office
Microsoft Word - KJMetzner_Publications_Oktober_2019.docx
... J. Fehr Efficacy of lead‐in silibinin and subsequent triple therapy in difficult‐to‐treat HIV ... silibinin prior to triple‐therapy translates into favorable treatment outcomes in difficult‐to‐treat HIV ... J. Fehr Efficacy of lead‐in silibinin and subsequent triple therapy in difficult‐to‐treat HIV ... silibinin prior to triple‐therapy translates into favorable treatment outcomes in difficult‐to‐treat HIV ...
Microsoft Word - 180208_Bibliography_Jan Fehr.docx
... , and the Swiss HIV Cohort Study. A lead-in with silibinin prior to triple-therapy translates into ... , Fehr J. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis ... , and the Swiss HIV Cohort Study. A lead-in with silibinin prior to triple-therapy translates into ... , Fehr J. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis ...
